Fludarabine and Arabinosylcytosine Therapy of Refractory and Relapsed Acute Myelogenous Leukemia

References

• Freireich E. Arabinosyl cytosine: A 20-year Update. J. Clin. Oncol 1987; 5: 523–524
   PubMed Web of Science ®Google Scholar
• Chu M., Fischer G. Comparative studies of Leukemia cells sensitive and resistant to cytosine arabinoside. Biochem. Pharmacol 1965; 14: 333–341
   PubMed Web of Science ®Google Scholar
• Estey E., Plunkett W., Dixon D., Keating M., McCredie K., Freireich E. Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia. Leukemia 1987; 1: 580–583
   PubMed Web of Science ®Google Scholar
• Gandhi V., Plunkett W. Modulation of arabinosyl nucleoside metabolism by arabinosylnucleotides in human Leukemia cells. Cancer Res 1988; 48: 329–334
   PubMed Web of Science ®Google Scholar
• Gandhi V., Estey E., Kemena A., Keating M., Plunkett W. Potentiation of arabinoslylcytosine triphosphate metabolism in Leukemia blasts by fludarabine monophosphate during therapy. Proc. Am. Soc. Clin. Oncol 1991; 10: 95
   Google Scholar
• Gandhi V., Estey E., Keating M., Plunkett W. Biochemical modulation of arabinosycytosine for therapy of leukemias. Leukemia and Lymphoma 1992, (in press)
   Google Scholar
• Warrell R., Berman E. Phase I and II study of fludarabine phosphate in leukemia: Therapeutic efficacy with delayed central nervous system toxicity. J. Clin. Oncol 1986; 4: 74–79
   PubMed Web of Science ®Google Scholar
• Spriggs D., Stopa E., Mayer R., Schoene W., Kufe D. Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: Phase I and neuropathological study. Cancer Res 1986; 46: 5953–5958
   PubMed Web of Science ®Google Scholar
• Chun H., Leyland-Jones B., Caryk S., Hoth D. Central nervous system toxicity of fludarabine phosphate. Cancer Treat. Rept 1986; 70: 1225–1228
   PubMedGoogle Scholar
• Keating M., Kantarjian H., O'Brien S., Roller C., Talpaz M., Schachner J., Childs C., Freireich E., McCredie K. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J. Clin. Oncol 1991; 9: 44–49
   PubMed Web of Science ®Google Scholar
• Keating M., Kantarjian H., Smith T., Estey E., Walters R., Andersson B., Beian M., McCredie K., Freireich E. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J. Clin. Oncol 1989; 7: 1071–1080
   PubMed Web of Science ®Google Scholar
• Hiddemann W., Martin W.-R., Sauerland C.-M., Heineike A., Biichner T. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: A proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse and standardized first line therapy. Leukemia 1990; 4: 184–188
   PubMed Web of Science ®Google Scholar
• Kantarjian H., Estey E., Plunkett W., Keating M., Walters R., Iacoboni M., McCredie K., Freireich E. Phase I–II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am. J. Med 1986; 81: 387–394
   PubMed Web of Science ®Google Scholar
• Plunkett W., Liliemark J., Adams T., Nowak B., Estey E., Kantarjian H., Keating M. Saturation of l-b˜-D-arabinosylcytosine 5′-triphosphate accumulation in Leukemia cells during high dose l-b˜-D-arabinofuranosylcyto-sine therapy. Cancer Res 1987; 47: 3005–3011
   PubMed Web of Science ®Google Scholar
• Danhauser L., Plunkett W., Keating M. J., Cabanillas F. 9-b˜-D-Arabinofuranosyl-2-fluoroadenine 5′-monophos-phate pharmacokinetics in plasma and tumor cells of patients with relapsed Leukemia and lymphoma. Cancer Chemother. Pharmacol 1986; 18: 145–152
   PubMed Web of Science ®Google Scholar
• Estey E., Plunkett W., Keating M., McCredie K., Freireich E. Cytosine arabinoside in intermediate doses' as therapy for patients with acute myelogenous leukemia. Proc. Am. Assoc. Cancer Res 1988; 29: 209
   Web of Science ®Google Scholar
• Estey E., Plunkett W., Kantarjian H., Rios M., Keating M. 1992, Cytosine arabinoside in intermediate doses for patients with acute myeloid leukemia. Leukemia Lymphoma in press
   Google Scholar
• Herzig R., Wolff S., Lazarus H., Phillips R., Karanes C., Herzig G. High-dose cytosine arabinoside therapy for refractory leukemia. Blood 1983; 62: 361–369
   PubMed Web of Science ®Google Scholar
• Preisler H., Epstein J., Barcos M., Priore R., Raza A., Growman R., Vogler R., Winton E., Grunwald H., Rai K., Brennan J., Bennett J., Goldberg A., Gottlieb A., Chervnick P., Joyce R., Miller K., Larson R., D'Arrigo P., Doeblin T., Stein M., Bloom M., Steel L., Lee H. Prediction of response of acute nonlymphocytic Leukemia to therapy with 'high-dose' cytosine arabinoside. Br. J. Haematol 1984; 58: 19–32
   PubMed Web of Science ®Google Scholar
• Vogler R., Preisler H., Winton H., Gottlieb A., Goldberg J., Brennan J., Grunwald H., Rai K., Growman G., Miller K., Chervenick P., Azarnia N. Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous Leukemia in relapse: A Leukemia intergroup study. Cancer Treat. Rpt 1986; 70: 455–459
   PubMedGoogle Scholar
• Willemze R., Fibbe W., Zwaan F. Experience with intermediate and high dose cytosine arabinoside in refractory acute leukemia. Oncologia 1983; 6: 200–204
   Google Scholar
• van Prooijen H., Dekker A., Punt K. The use of intermediate dose cytosine arabinoside (ID-AraC) in the treatment of acute non-lymphoblastic leukemia in relapse. Br. J. Haematol 1984; 57: 291–299
   PubMed Web of Science ®Google Scholar
• Estey E., Kantarjian H., Freireich E., McCredie K., Deisseroth A., Keating M. Long-term results with continuous-infusion high-dose ara-C as primary treatment of newly-diagnosed AML. Proc. Am. Soc. Clin. Oncol 1990; 9: 212
   Google Scholar
• Samuels B., Larson R., Le Beau M., Daly K., Bitter M., Bardiman J., Barker C., Rowley J., Golumb H. Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo. Leukemia 1988; 2: 79–83
   PubMed Web of Science ®Google Scholar
• Keating M., Smith T., Kantarjian H., Cork A., Walters R., Trujillo J., McCredie K., Gehan E., Freireich E. Cytogenetic pattern in acute myelogenous leukemia. A major reproducible determinant of outcome. Leukemia 1988; 2: 403–412
   PubMed Web of Science ®Google Scholar
• Schiffer C., Lee E., Tomiyasu T., Wiernik P., Testa J. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood 1989; 73: 263–270
   PubMed Web of Science ®Google Scholar
• Koistinen P., Wang C., Yang G., Williams D., Lyman S., Minden M., McCulloch E. OCI/AML-4 an acute myeloblastic leukemia cell line: Regulation and response to cytosine arabinoside. Leukemia 1991; 5: 704–711
   PubMed Web of Science ®Google Scholar